Advertisement
Advertisement
U.S. markets close in 3 hours 44 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Trevena, Inc. (TRVN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.5131-0.0110 (-2.10%)
As of 12:13PM EST. Market open.
Advertisement

Trevena, Inc.

955 Chesterbrook Boulevard
Suite 110
Chesterbrook, PA 19087
United States
610 354 8840
https://www.trevena.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees25

Key Executives

NameTitlePayExercisedYear Born
Ms. Carrie L. BourdowPres, CEO & Director1.14MN/A1963
Dr. Mark A. DemitrackSr. VP & Chief Medical Officer725.67kN/A1958
Dr. Howard A. Rockman M.D.Scientific Founder, Consultant and Member of Scientific Advisory BoardN/AN/AN/A
Mr. Barry ShinSr. VP & CFON/AN/A1972
Mr. Michael CatalanoVP of MarketingN/AN/AN/A
Mr. Robert T. YoderSr. VP, Chief Bus. Officer & Head of Commercial OperationsN/AN/A1966
Ms. Patricia M. DrakeChief Commercial OfficerN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist that has completed Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Corporate Governance

Trevena, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement